Standout Papers

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug 2002 2026 2010 2018 1.0k
  1. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (2002)
    Renaud Capdeville, Elisabeth Buchdunger et al. Nature Reviews Drug Discovery

Immediate Impact

5 by Nobel laureates 34 from Science/Nature 70 standout
Sub-graph 1 of 22

Citing Papers

Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
2020 Standout
1 intermediate paper

Works of Alex Matter being referenced

First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
2017
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
2002 Standout

Author Peers

Author Last Decade Papers Cites
Alex Matter 928 401 167 389 36 2.0k
Renee D. Wright 1776 423 236 364 28 2.5k
Rina Plattner 1085 448 129 120 38 1.8k
Daikichi Fukushima 793 230 176 309 31 1.8k
Richard M. Nelson 1300 298 640 351 49 3.0k
Malaiyalam Mariappan 1352 251 162 148 61 2.5k
Robert L. Simmer 1387 352 167 262 25 2.2k
Carol S. Lim 1290 311 156 138 67 2.0k
Nozomi Yamaguchi 891 376 261 109 71 2.2k
David G. Sanford 843 406 194 171 29 1.5k
Matthew J. Taylor 641 233 116 205 30 1.7k

All Works

Loading papers...

Rankless by CCL
2026